柔肝化纤合剂联合阿德福韦酯胶囊治疗气滞血瘀型乙型肝炎肝纤维化82例

A Clinical Observation of Liver Fiber Mixture Combined with Adefovir Dipivoxil Capsules in Treatment of Qi-stagnancy and Blood Stasis Type Hepatitis with Hepatic Fibrosis

摘要:

目的：探讨柔肝化纤合剂联合阿德福韦酯胶囊治疗气滞血瘀型乙型肝炎肝纤维化的临床疗效。方法：治疗组82例采用院内制剂柔肝化纤合剂联合阿德福韦酯胶囊治疗；对照组82例采用阿德福韦酯胶囊联合其他常规保肝药物。12个月后观察两组患者超声指标及血生化指标。结果：治疗后，治疗组患者Ⅲ型前胶原（PC_Ⅲ）、透明质酸（HA）、脯氨酸肽酶（PLD）、Ⅳ型胶原（Ⅳ-C）、层粘连蛋白（LN）、丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、 总胆红素（TBIL）、白蛋白（ALB）、肝门静脉（hpv）和脾静脉（sv）内径和脾脏的厚度均较对照组降低，差异有统计学意义。结论：柔肝化纤合剂联合阿德福韦酯胶囊能有效改善气滞血瘀型乙型肝炎肝纤维化的肝功能、肝纤维化及超声学指标，具有治疗和逆转肝纤维化的作用。

Abstract:

Objective: Explore soft liver chemical fiber mixture joint adefovir capsule on the clinical effect of qi-stagnancy and blood stasis type liver fibrosis. Method: The treatment group 82 examples using soft liver chemical fiber mixture joint adefovir capsule treatment; the control group 82 patients taking adefovir capsule and other conventional protect liver drugs. After 12 months observation serum immunology and the ultrasonic index index. Result: After treatment, the treatment group patients with liver function index, liver fibrosis indexes and ultrasonics index significantly lower than the control group, the difference was statistically significant. Conclusion: Soft liver fiber mixture combined with adefovir dipivoxil capsules can improve liver fibrosis and ultrasonic liver function, qi-stagnancy and blood stasis type hepatitis B liver fibrosis indexes, with treatment and reversing hepatic fibrosis.